NCI-2020-04796

First-in-Human, Phase 1/1b, Open-label, Multicenter Study ofBifunctional EGFR/TGF? Fusion Protein BCA101 Monotherapyand in Combination Therapy in Patients with EGFR-DrivenAdvanced Solid Tumors

This is a Phase 1/1b first-in-human study designed to investigate the safety, efficacy, and tolerability of BCA101, a novel treatment that targets both EGFR (epidermal growth factor receptor) and TGFβ (transforming growth factor beta), in patients with advanced solid tumors driven by EGFR. BCA101 will be assessed both on its own and when used with other treatments, aiming to inhibit EGFR signaling and modify the tumor microenvironment by targeting TGFβ, ultimately aiming for improved anti-tumor effects.

EGFR: Epidermal Growth Factor Receptor (EGFR) is on the surface of cells and helps them grow and divide. In cancer, EGFR is like a switch that gets stuck in the "on" position, making cells grow and divide too much.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04429542

Clinical Trial Site: Columbia

To see all available clinical trials click here.